Small Molecules Acquired in 2021 M&A: Deep Dive

Tuesday June 7, 2022

18 mins read

There were 16 acquisitions of companies with small molecule drug assets in 2021 and one merger. Here is a more in-depth look into all of the lead small molecules acquired in 2021, including a review of:

The lead molecules in each acquisition and their structural representations where disclosed
The mechanism of action, stage, and indication of each lead molecule
Relevant clinical data and rationale for each acquisition

this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.

Navigate the 2021 M&A Series

RECENT ARTICLES

2021 First-in-Class Large Molecule Drug Approvals (Pt. III)June 26, 2022
May 2022 Molecules of the Month Runners UpJune 24, 2022
Shaken by An Unexpected Patient ConnectionJune 20, 2022
Molecules of the Month – May 2022June 18, 2022
Drug Hunter In-Person EventsJune 16, 2022
Acceleron’s TGF-beta Ligand Trap, Trillium’s SIRP-alpha Fusion Proteins, and Eight Other Large Molecules Acquired in 2021June 10, 2022

DRUG DISCOVERY RESOURCES

JOIN SUBSCRIBERS from